



20th ADVAC Advanced Course of Vaccinology

Les Pensières
Veyrier-du-Lac
(FRANCE)
**13-24 May
2019**
Application deadline:
15 November 2018

For 20 years, ADVAC has provided senior decision-makers and scientists in the field of vaccines with a comprehensive overview of the latest advances, from immunology to vaccine development, including clinical trials. The social, economic, political and ethical issues of vaccination are also addressed during the lectures, which are given by a faculty of leading global experts.

OVER 1,100 ADVAC ALUMNI WORLDWIDE

Through alumni get-together meetings and a variety of online resources (website, newsletters), ADVAC continues to bring together vaccinologists throughout the world to discuss the major challenges of the day.

The relationships forged at ADVAC remain strong through meetings organised during international conferences such as SAGE, ESPID (European Society for Paediatric Infectious Diseases), WSPID (World Society for Pediatric Infectious Diseases) or IDSA (Infectious Diseases Society of America).

72 HIGHLY SELECTED PARTICIPANTS

70 INTERNATIONAL SPEAKERS

13 INTERACTIVE SESSIONS

11 DAYS OF KNOWLEDGE-SHARING

19 SUCCESSFUL YEARS

10 CASE STUDIES

1 DIPLOMA AND CME CERTIFICATE

A NETWORK OF OVER 1,100 ALUMNI

For the 20th ADVAC, CME credits will be requested from the European Union of Medical Specialists - European Accreditation Council for Continuing Medical Education (UEMS-EACCME). CME credits can be converted by the American Medical Association (AMA).

WHO SHOULD APPLY ?

- Scientists and decision-makers involved in vaccine development, in the elaboration of new vaccination strategies or in policy decisions related to the introduction of new vaccines in public health programmes, at national or international levels.
- For both the public and private sectors.

Apply online through <http://advac.org>
Deadline: 15 November 2018 at 12:00 GMT.

SELECTION CRITERIA

Participants (maximum 72) will be selected by the international scientific committee, according to their:

- Educational background,
- Involvement in vaccinology,
- Decision-making responsibility in vaccinology,
- Expected impact of the course at personal, institutional and national levels (maximum one participant per institution).

PROGRAMME FEES

Accommodation fees: 2,400 €
Registration fees:

- Participants from academic/governmental institutions & NGOs benefit from reduced fees: 1,500 € VAT included
- Participants from industry:
SME and ADVAC sponsors from industry: 4,000 €
Other industry participants: 9,000 €

The fees include tuition and course materials for the full period of the course. If selected, participants will be required to pay all fees in full to confirm their participation.

Fellowships:

Fellowships covering travel expenses, registration and accommodation fees will be available for participants from low and middle income countries (with the support of the Bill & Melinda Gates Foundation). They will be handled by the Center of Vaccinology at the University of Geneva and the Mériex Foundation. Fellowships will also be provided to selected ESPID members. Candidates wishing to apply for such fellowships should tick the appropriate box on their application and if selected, ADVAC organisers will inform the relevant fellowship provider.

VENUE

The course will be held at the Mériex Foundation's conference centre, Les Pensières Center for Global Health, at Veyrier-du-Lac, on the scenic banks of Lake Annecy (France). Accommodation will be arranged in nearby hotels.

CONTACT

advac@fondation-merieux.org
or advac@unige.ch
See additional info on <http://advac.org>
www.fondation-merieux.org



Organised by
The Mériex Foundation and University of Geneva

with the co-sponsorship of

- European Commission (EDCTP)
- World Health Organization

and

- European Centre for Disease Prevention and Control (ECDC)
- Centers for Disease Control and Prevention (CDC)
- European Society for Paediatric Infectious Diseases (ESPID)

- Johns Hopkins Bloomberg School of Public Health
- National Foundation for Infectious Diseases (NFID)
- National Institutes of Health (NIH) and Fogarty International Center

Fellowships for low and middle income country participants provided by

- Bill & Melinda Gates Foundation



03-19 - Credit photo: E. Bergnaud, A. Bouvier, F. Leclerc, S. Stock - Mériex - RCS Lyon B 398 160 242



Neal Halsey,
Professor - Department
of International Health,
Bloomberg School of Public
Health, Baltimore

“ ADVAC helps fulfill the prescient vision of Dr. Charles Mérieux to gather scientists and other health professionals to address the never-ending challenges from infectious diseases. Past ADVAC participants have helped bring new lifesaving vaccines to countries throughout the world and they are playing key roles in the development of new vaccines. ”



Objective: to facilitate critical decision-making in vaccinology by providing participants with a comprehensive overview of the field, from immunology to vaccine development, including clinical trials and the social, economic, political and ethical issues of vaccination.



PROVISIONAL PROGRAMME

SESSION 1

THE MULTI-FACETED NATURE OF VACCINOLOGY

- Access to vaccination in GAVI countries and, at global level
- Impact of vaccination on disease epidemiology
- Are vaccines always cost-effective?
- How to develop a new programme of immunisation
- Industrial vision of vaccinology in industrialised and developing countries

SESSION 2

HOW VACCINES WORK

- How are vaccine responses elicited?
- Immunological basis for responses to mucosal vaccines
- Immunological correlates of immunity
- Vaccines and immunological memory

SESSION 3

DECISION-MAKING IN VACCINE R&D

- New approaches to vaccine development and delivery
- How do vaccines cause adverse events
- From pre-clinical research to vaccine development
- Vaccine adjuvants: pragmatic approaches

SESSION 4

ASSESSING VACCINES IN CLINICAL TRIALS (I)

- Sequential stages of clinical trials and overview of issues to be considered
- How to design, recruit volunteers for, and analyse the results of selected phase II trials
- How to design a phase II trial

SESSION 5

ASSESSING VACCINES IN CLINICAL TRIALS (II)

- Lessons from pitfalls experienced in the registration process
- Clinical trials: role of a Data and Safety Monitoring Board (DSMB)
- Designing and analysing the results of 3 selected phase III trials

SESSION 6

VACCINE SAFETY

- Lessons from previous adverse effects of vaccination and assessment of causal relationships
- Immunological safety of vaccination
- Population-based post-licensure surveillance
- Immunisation safety in developing country vaccination programmes
- Vaccine hesitancy and risk communication: an overview

SESSION 7

ETHICAL ISSUES

- Ethical issues related to clinical trials
- Group exercises

SESSION 8.1

INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES

- Approaches to help the decision-making process
- Role of epidemiology and the economy
- Case-specific studies: Meningococcal vaccines, Combination vaccines, Influenza-vaccination strategies, Pneumococcal conjugates, HPV, Rotavirus, JE, Dengue
- Group exercises: selected countries

SESSION 8.2

INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES

- Vaccination in the elderly
- Influenza biology
- New vaccines: Malaria, Tuberculosis, HIV, RSV
- Rotavirus vaccines
- Dengue vaccines
- HPV vaccines

SESSION 9

SELECTING APPROPRIATE VACCINATION STRATEGIES

- Vaccines for maternal-neonatal health
- Vaccination schedules
- Elimination and eradication strategies

SESSION 10

FACING THE MEDIA

- Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups

CORE FACULTY

ROY ANDERSON

Imperial College London, UK

EDWIN ASTURIAS

Children's Hospital Colorado, USA

NORMAN BAYLOR

BCG, USA

RON DAGAN

Soroka Medical Center, Israel

PHILIPPE DUCLOS

University of Geneva, Switzerland

JANET ENGLUND

Seattle Children's Hospital, USA

ADAM FINN

University of Bristol, UK

BERNARD FRITZELL

BFL Conseils, France

DAVID GOLDBLATT

Institute of Child Health, University College London, UK

DEBORAH HALL

Journalist, UK

NEAL HALSEY

J.H. Bloomberg School of Public Health, USA

CAROLE HEILMAN

Formerly NIAID, NIH, USA

KARI JOHANSEN

ECDC, Sweden

PAUL-HENRI LAMBERT

University of Geneva, Switzerland

MYRON LEVINE

University of Maryland, USA

NONI MCDONALD

Dalhousie University, Canada

MARK MILLER

Fogarty International Center, NIH, USA

RICHARD MOXON

Oxford University, UK

PIETER NEELS

Vaccine-Advice, Belgium

KATHY NEUZIL

CVD Baltimore, USA

HANNA NOHYNEK

National Institute for Health and Welfare, Finland

UMESH PARASHAR

CDC, USA

ANDREW POLLARD

Oxford University, UK

STANLEY PLOTKIN

Vaxconsult, USA

DAVID SALISBURY

Chatham House, UK

CLAIRE-ANNE SIEGRIST

University of Geneva, Switzerland

CATHERINE SLACK

University of KwaZulu-Natal, South Africa

PETER SMITH

London School of Hygiene & Tropical Medicine, UK

SCIENTIFIC COMMITTEE

EDWIN ASTURIAS

Children's Hospital Colorado, USA

JULIET BRYANT

Mérieux Foundation, France

PHILIPPE DUCLOS

University of Geneva, Switzerland

ADAM FINN

University of Bristol, UK

MARTIN FRIEDE

WHO, Switzerland

NEAL HALSEY

J.H. Bloomberg School of Public Health, USA

CAROLE HEILMAN

Formerly NIAID, NIH, USA

KARI JOHANSEN

ECDC, Sweden

PAUL-HENRI LAMBERT

University of Geneva, Switzerland

ORIN LEVINE

Bill & Melinda Gates Foundation, USA

MICHAEL MAKANGA

EDCTP, the Netherlands

MARK MILLER

Bethesda, USA

HANNA NOHYNEK

THL, Finland

STANLEY PLOTKIN

(Senior Scientific Advisor) Vaxconsult, USA

CLAIRE-ANNE SIEGRIST

University of Geneva, Switzerland

KEIPP TALBOT

NFID, USA

MELINDA WHARTON

CDC, USA